NEXT Oncology- Virginia

Running trials

• Recruiting

  Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic

  NCT07807345· Phase 1· Source

• Recruiting

  Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML

  NCT07723703· Phase 1· Source

• Recruiting

  A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-663 in Participants With Relapsed or Refractory Myeloid Malignancies, Advanced Solid Tumors, or Recurrent or Progressive Glioblastoma.

  NCT07779798· Phase 1· Source

• Recruiting

  A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies

  NCT07542704· Phase 1· Source

• Recruiting

  AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

  NCT07454642· Phase 1· Source

• Recruiting

  A 2-part Phase 1/2 Open-label Trial on ODM-212

  NCT07563738· Phase 1/2· Source

• Recruiting

  A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

  NCT07277413· Phase 1· Source

• Recruiting

  Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

  NCT07424547· Phase 1· Source

• Recruiting

  A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

  NCT07361562· Phase 1· Source

• Recruiting

  A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

  NCT07174583· Phase 1/2· Source

• Recruiting

  A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

  NCT07169734· Phase 1/2· Source

• Recruiting

  A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

  NCT07094204· Phase 1· Source

• Recruiting

  Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

  NCT07080242· Phase 1· Source

• Recruiting

  A Study of PHST001 in Advanced Solid Tumors

  NCT06840886· Phase 1· Source

• Recruiting

  A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC

  NCT06785636· Phase 1/2· Source

• Active, not recruiting

  Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors

  NCT06781983· Phase 1· Source

• Recruiting

  A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors

  NCT06747585· Phase 1/2· Source

• Recruiting

  A Study of DM005 in Patients With Advanced Solid Tumors

  NCT06515990· Phase 1/2· Source

• Recruiting

  A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

  NCT06326411· Phase 1· Source

• Active, not recruiting

  First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

  NCT06239467· Phase 1· Source

• Recruiting

  Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

  NCT06162221· Phase 1/2· Source

• Recruiting

  Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

  NCT06128551· Phase 1/2· Source

• Active, not recruiting

  A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

  NCT05873686· Phase 1· Source

• Recruiting

  IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

  NCT06119685· Phase 1/2· Source

• Recruiting

  Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

  NCT06040541· Phase 1· Source

• Active, not recruiting

  Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

  NCT05887492· Phase 1/2· Source

• Recruiting

  Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

  NCT05732831· Phase 1/2· Source

• Recruiting

  A Study of ASP1002 in Adults for Treatment of Solid Tumors

  NCT05719558· Phase 1· Source

• Active, not recruiting

  A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer

  NCT05653752· Phase 1· Source

• Active, not recruiting

  Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

  NCT05462717· Phase 1· Source

• Recruiting

  A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

  NCT05377996· Phase 1/2· Source

• Recruiting

  Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

  NCT05379985· Phase 1/2· Source

• Active, not recruiting

  TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

  NCT04485013· Phase 1· Source

• Recruiting

  Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

  NCT03715933· Phase 1· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer17 recruiting
• Colorectal cancer10 recruiting
• Pancreatic cancer7 recruiting
• Endometrial cancer4 recruiting
• Gastric and esophageal cancer4 recruiting
• Ovarian cancer4 recruiting
• Bladder cancer3 recruiting
• Head and neck cancer3 recruiting
• Liver and biliary tract cancer3 recruiting
• Mesothelioma3 recruiting
• Prostate cancer3 recruiting
• Sarcoma3 recruiting
• Melanoma2 recruiting
• Neuroendocrine tumours2 recruiting
• Acute myeloid leukemia1 recruiting
• Childhood cancers1 recruiting
• Glioblastoma1 recruiting
• Multiple myeloma1 recruiting
• Myelodysplastic syndromes1 recruiting
• Triple-negative breast cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

  NCT06433219· Phase 2· Source

• Recruiting

  A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946

  NCT06616766· Phase 1/2· Source

• Terminated

  Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

  NCT06287463· Phase 1· Source

• Terminated

  A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors

  NCT06364696· Phase 1· Source

• Completed

  A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors

  NCT06403436· Phase 1· Source

• Terminated

  A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors

  NCT05716295· Phase 1/2· Source

• Completed

  Study Of ATRN-119 In Patients With Advanced Solid Tumors

  NCT04905914· Phase 1/2· Source

• Withdrawn

  A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies

  NCT05279859· Phase 1/2· Source

• Terminated

  Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

  NCT04868877· Phase 1/2· Source

• Completed

  A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer

  NCT03819387· Phase 1· Source